Vancouver, British Columbia, February 23, 2007 –Protox TM Therapeutics Inc. (TSX-V:PRX) today announced that additional pre-clinical efficacy and safety data on PRX302, a novel pore-forming targeted toxin, will be presented this week at the Prostate Cancer Symposium, a gathering sponsored by the American Society of Clinical Oncology (ASCO).
